Gregory Yuen
Psychiatry · Honolulu, HINPI 1871654640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,457 and has fallen 80.4% since, to $286 in 2025. Among psychiatry clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Sunovion Pharmaceuticals Inc.$871
- Neurocrine Biosciences, Inc.$737
- AbbVie$678
- Otsuka America Pharmaceutical, Inc.$601
- Alkermes, Inc.$564
- plus $2K from 7 others
What the payments were for
- Food & beverage$6,23999%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $1,214 |
| Sunovion Pharmaceuticals Inc. | 46 | $871 |
| Neurocrine Biosciences, Inc. | 24 | $737 |
| AbbVie(2 entities) | 41 | $678 |
| Otsuka America Pharmaceutical, Inc. | 28 | $601 |
| Alkermes, Inc. | 28 | $564 |
| Lundbeck LLC | 29 | $518 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $402 |
| Teva Pharmaceuticals USA, Inc. | 17 | $373 |
| Indivior Inc. | 8 | $154 |
| Axsome Therapeutics, Inc. | 2 | $121 |
| Merck | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,295 in reported general payments places this provider in the 95th percentile of 183 psychiatry providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 27 | $8,640 |
| Aripiprazole | 48 | $4,237 |
| Quetiapine Fumarate | 83 | $3,334 |
| Clozapine | 50 | $2,558 |
| Divalproex Sodium ErDivalproex Sodium | 29 | $2,328 |
| Ziprasidone Hcl | 43 | $2,271 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 54 | $2,118 |
| Olanzapine | 49 | $1,817 |
| Fluoxetine Hcl | 25 | $1,695 |
| Bupropion XlBupropion Hcl | 24 | $890 |
| Trazodone Hcl | 24 | $874 |
| Lamotrigine | 17 | $651 |
| Prazosin Hcl | 11 | $593 |
| Mirtazapine | 19 | $540 |
| Gabapentin | 17 | $361 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Honolulu
- Denis Mee-LeeHonolulu$526K
- David SteinHonolulu$186K
- Raymond DavidsonHonolulu$6K
- Helen Blaisdell-BrennanHonolulu$6K
- Glorifin BelmonteHonolulu$5K
- Brett LuHonolulu$5K
- Donna McBrien SliwowskiHonolulu$4K
- Alan BuffensteinHonolulu$3K
- Nancy LuckieHonolulu$3K
- Angela KingHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.